Miracle Shot Ends Food Allergy Fears

A single injection could soon let children with multiple food allergies safely eat peanuts, milk, eggs, and more without fear of deadly reactions.

Story Snapshot

OUtMATCH trial proves omalizumab (Xolair) builds tolerance to multiple foods in over 60% of participants after 52 weeks.
FDA approved Xolair in 2024 for kids over age 1, with 50,000 users in one year amid Palforzia’s market exit.
Immune changes reduce pro-allergic T cells and dendritic cells, shifting treatment from symptoms to prevention.
Long-term data from AAAAI 2026 shows sustained daily consumption of allergens like 300 mg median.
Experts hail fastest drug uptake ever, easing family life and enabling normal activities.

OUtMATCH Trial Launch and Design

CoFAR launched the OUtMATCH study in 2019 across 10 U.S. sites. Researchers screened 479 participants and enrolled 180 children allergic to peanuts plus two other foods such as milk, eggs, wheat, cashews, hazelnuts, or walnuts. The NIH-funded trial tested omalizumab combined with multi-food oral immunotherapy. Stage 1 lasted 16-20 weeks with omalizumab or placebo injections. Stage 2 added oral immunotherapy up to 52 weeks, culminating in food challenges.

Immune Modulation Mechanisms Revealed

Omalizumab blocks IgE antibodies, originally approved for asthma in 2003. In Stage 1, it reduced IL-4+ peanut-reactive CD4+ T cells and FcεRI+ dendritic cells. Stage 2 data linked lower OX40L+ dendritic cells to challenge success. Xiaoying Zhou, PhD from Harvard, led immune profiling showing these shifts predict tolerance. This reprogramming targets root causes, not just symptoms.

Dietary Success and FDA Milestone

After 52 weeks, over 60% of participants tolerated significant allergens via daily plans, median 300 mg across foods. R. Sharon Chinthrajah, MD from Stanford, analyzed data showing equivalence between omalizumab and placebo groups at 12 months. FDA approved Xolair for food allergies in patients over age 1 in February 2024 based on these results. Robert Wood, MD from Johns Hopkins and CoFAR lead, noted its protection against accidental exposures.

Participants advanced from trace amounts to equivalents like half a cup of milk or half an egg. AAAAI presented long-term data February 27 to March 2, 2026, in Philadelphia, confirming sustained tolerance without group differences.

Rapid Adoption Fills Treatment Gaps

Xolair reached 50,000 users in a year, the fastest uptake Wood has seen due to unmet needs. Palforzia, limited to peanuts, ends production July 2026, creating a void omalizumab fills for multi-allergens. Biosimilars like OMLYCLO emerge to improve affordability. Families report eased daily life; one patient traveled to Egypt enjoying cultural foods. CoFAR’s diverse demographics ensure broad applicability.

Short-term impacts cut reaction risks at schools and meals. Long-term, it may become standard management, boosting biologics and trials like ILIT.

Expert Consensus on Transformative Shift

Chinthrajah called dietary success clinically meaningful for food introductions. Zhou identified predictors like myeloid dendritic cell frequencies for outcomes. Wood emphasized reduced anaphylaxis risks. Apex Allergy experts stress pediatric real-life benefits, complementing Viaskin patches. Consensus views omalizumab as game-changing management, not a cure, backed by consistent trial data.